| Important Contact Information | | Important Information for Health Care Providers | including diabetic ketoacidosis, hypothyroidism, hyperthyroidism, and | related and other adverse reactions with pembrolizumab. Consultation with | Tell your doctor right away if you have any of these symptoms: |
|-------------------------------|----------------------------------|--|---|---|--|
| Name of Doctor Office Phone | My Name My Phone | This patient is being treated with pembrolizumab, which can cause immune-related adverse reactions that may appear any time during treatment or even after treatment. Assess patients for signs and symptoms of immune-related adverse reactions. Early diagnosis and appropriate management are essential to minimise any consequences of | thyroiditis), immune-related skin adverse reactions, other immune-related adverse reactions (uveitis, arthritis, myositis, myocarditis, pancreatitis, Guillain-Barre syndrome, solid organ transplant rejection following pembrolizumab treatment in donor organ recipients, myasthenic syndrome, haemolytic anaemia, sarcoidosis and encephalitis). Severe infusion-related reactions have | an oncologist or other medical specialist may be helpful for management of organ-specific immune-related adverse reactions. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance; Website: www.hpra.ie. | Lungs Shortness of breath Chest pain Coughing |
| After-hours Phone | Emergency Contact (Name & Phone) | immune-related adverse reactions. The following immune-related adverse reactions have been reported: immune-related pneumonitis, immune-related colitis, immune-related hepatitis, immune-related nephritis, immune-related nephritis, immune-related endocrinopathies (including hypophysitis, type 1 diabetes mellitus, | also been reported. For suspected immune-related adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Please refer to the SmPC for pembrolizumab, available at www.ema. europa.eu, for detailed information on monitoring and managing immune- | Please consult the Summary of Product Characteristics for KEYTRUDA at medicines.ie or call MSD Medical Information at 01 299 8700 for more information. | |

- Yellowing of skin or whites of eyes
- Dark urine
- Bleeding or bruising more easily than normal

Kidnevs

 Changes in the amount or color of your urine

Hormone glands

- Rapid heartbeat
- Weight loss or weight gain
- Increased sweating
- Hair loss
- Feeling cold
- Constipation Deeper voice

- Muscle aches
- Dizziness or fainting
- Headaches that will not go away or unusual headache

Type 1 diabetes

- Feeling more hungry or thirsty
- Needing to urinate more often
- Weight loss

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance; Website: www.hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.

Patient Alert Card

For more information, consult the Package Leaflet for KEYTRUDA containing information for the patient at medicines.ie.



Red Oak North, South County Business Park, Leopardstown, Dublin D18 X5K7, Ireland. © Merck Sharp & Dohme B.V. 2020.

All rights reserved. Date of revision: March 2020

IMPORTANT

- Do not attempt to diagnose or treat side effects yourself.
- Take this card with you at all times, especially when you travel, whenever you go to the emergency room, or when you must see another
- doctor. Be sure to notify any health care professional you see that you are being treated with pembrolizumab and show them this card.

KEYTRUDA® (pembrolizumab)

May cause some serious side effects which can sometimes become life-threatening and lead to death. These may happen any time during treatment or even after vour treatment has ended. You may experience more than one side effect at the same time.

Contact your doctor right away if you develop any signs or symptoms including those not listed on this card. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. Your doctor may withhold the next dose of pembrolizumab or stop treatment with pembrolizumab.